financial results

The firm's CEO said it is experiencing a strong commercial launch of its CODX Molecular Diagnostics System, not yet reflected in its reported revenues. 

The company attributed the drop in revenue to delays in some placements of its Unyvero molecular diagnostic system.

The company attributed the decline in revenues to changes it is making in the billing process for its diagnostics.

The company said the planned commercial launch of its noninvasive lung cancer diagnostic has been delayed due to technical issues during the test's validation process.

The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

The company fell short of the consensus Wall Street revenue estimate, while its net loss for the quarter also widened.

The company had $1.1 million in revenue during the quarter, a 10 percent increase year over year despite what the firm said was a 15 to 20 percent sales reduction due to recent hurricanes.

Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.

The revenue increase was primarily driven by increased revenue in the company's biopharma services, clinical services, and discovery services divisions.

The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.